Why Is Chembio Diagnostics (NASDAQ: CEMI) The Best Stock Of The Day?

Chembio Diagnostics is a biotech firm based in Hauppauge, New York that develops powerful diagnostic tools for medical applications the world over. The company keeps a global network of offices to ensure it can serve global clients, working from both Germany and Brazil.

Chembio Diagnostics (NASDAQ: CEMI)

This time last year, CEMI was trading at about the same price. It has seen a few spikes over that time related to news regarding its research, and it is currently recovering from a selloff earlier in the year.

Why is CEMI Moving?

CEMI stock is currently on the move after Brazil ordered $28M in COVID tests from the firm. The rapid test was verified as commercially viable in the spring, and this massive order boosted investor confidence. Because COVID-19 cases are rising in certain parts of the world, more test orders could occur at any time.

Where to Buy Chembio Diagnostics Stock

Choose from the brokers listed below—Benzinga’s favorites—to invest in CEMI stock. You can invest slowly at first, increase your position, diversify your portfolio and build wealth using tools provided by any of these brokers.

Stay Ahead of the Game on CEMI

Use Benzinga Pro when you need investment information that will dramatically improve your life, increase your net worth and help you stay ahead of the game on CEMI and other stocks.

Data for Chembio Diagnostics as of July 21, 2021

Summary of Chembio Diagnostics as of July 21, 2021:

  • Price Change: $2.06 to $4.0

  • 52 Week Low: $2.06

  • 52 Week High: $8.75

  • Market Cap: $49.802M

  • P/E Ratio: –

  • Dividend Yield: –

Significant Dates for Chembio Diagnostics:

  • Next Earnings Date: August 5th, 2021

  • Last Earnings Date: –

  • Ex-Dividend Date: –

  • Dividend Payment Date: –

Technical Data of Chembio Diagnostics as of July 21, 2021:

  • RSI: ⮕ 67.7824

  • MACD: Signal Line (-0.5347) Under MACD (-0.1691) ⮕ Bearish

  • Bollinger Bands: Price ($4.0), 20-Day SMA ($3.2983), Lower Band ($2.0137), Upper Band ($5.0769) ⮕ Neutral

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Roy Walsh

Roy Walsh

Related post